Trial Profile
Phase 1 Study of the Safety, Toxicity, Pharmacokinetics, Pharmacodynamics and Luminal Distribution of Single-dose DuoGel Through Rectal Administration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2021
Price :
$35
*
At a glance
- Drugs IQP 0528 (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 11 Mar 2020 Results (n=7) assessing safety and tolerability of IQP-0528 gel, presented at the 27th Conference on Retroviruses and Opportunistic Infections.
- 10 Oct 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 30 May 2019 to 30 Nov 2019.